Tumor-associated ligands of Natural Killer cell receptors (NKRLs)

Tumor-associated ligands of Natural Killer (NK) cell receptors are a diverse group of cell surface proteins that are typically upregulated on malignant cells in response to cellular stress, DNA damage, or oncogenic transformation. These ligands interact with a variety of activating receptors (such as NKG2D, NKp30, and DNAM-1) or inhibitory receptors (such as NKG2A and KIRs) expressed on NK cells and certain T cell subsets (PMID: 30305468). Activating ligands like MICA, MICB, and ULBPs serve as critical signals for the immune system to identify and eliminate "stressed" or transformed cells through NK cell-mediated cytotoxicity and proinflammatory cytokine release (PMID: 21734677). Conversely, many tumors upregulate inhibitory ligands, such as HLA-E or HLA-G, to engage inhibitory checkpoints and evade immune surveillance (PMID: 30504767). Therapeutic strategies targeting these ligands include monoclonal antibodies to block inhibitory interactions, bispecific engagers that bridge tumor ligands to NK cell activating receptors, and CAR-NK cells engineered to recognize specific ligands like B7-H6 (PMID: 19465914). A major challenge in this field is the proteolytic shedding of these ligands from the tumor surface, which generates soluble decoys that can systemically inhibit NK cell function and facilitate tumor escape (PMID: 12114504).

Other names

NK cell receptor ligandsNKG2D ligandsStress-induced ligandsNKp30 ligandsNatural killer cell activating ligandsNatural killer cell inhibitory ligands

Enhancement of NK cell-mediated cytotoxicity through the engagement of activating receptors or the blockade of inhibitory ligand-receptor interactions.